Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition

  • Roche Holdings AG RHHBY has announced results from the global phase 3 COMMODORE 2 study, evaluating the efficacy and safety of crovalimab in treatment-naive people with paroxysmal nocturnal hemoglobinuria (PNH). 
  • The study met its co-primary efficacy endpoints of transfusion avoidance and control of hemolysis (the ongoing destruction of red blood cells measured by lactate dehydrogenase levels). 
  • Also Read: Roche Flags Lower 2023 Sales On Declining Demand For COVID-19 Treatment, Diagnostics.
  • Results showed that crovalimab, given as a subcutaneous injection every four weeks, achieved disease control and was non-inferior to eculizumab, a current standard of care, which is given intravenously every two weeks.
  • The efficacy and safety data from the separate phase 3 COMMODORE 1 study in people with PNH switching from currently approved C5 inhibitors to crovalimab, supported the favorable benefit-risk profile of crovalimab, as seen in the pivotal COMMODORE 2 study.
  • PNH is a rare and life-threatening condition in which the complement system destroys red blood cells.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!